サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1653292

肺動脈性肺高血圧症の世界市場レポート 2025年

Pulmonary Arterial Hypertension Global Market Report 2025

出版日
ページ情報
英文 200 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
肺動脈性肺高血圧症の世界市場レポート 2025年
出版日: 2025年02月11日
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

肺動脈性肺高血圧症の市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は8.8％で、129億7,000万米ドルに成長します。予測期間の成長は、肺動脈性肺高血圧症に対する新規治療法の採用、早期発見・診断への注目の高まり、PAH治療薬・治療法のパイプラインの増加、PAH治療におけるプレシジョンメディシンの統合、新興市場におけるヘルスケアインフラの拡大などに起因すると考えられます。予測期間における主な動向には、医療画像および診断技術の進歩、医薬品開発のための連携やパートナーシップ、肺動脈性肺高血圧症管理における患者中心のアプローチ、併用療法の増加などが含まれます。

肺動脈性肺高血圧症市場の成長は、肺動脈性肺高血圧症（PAH）疾患の有病率の増加によって推進されています。PAH患者の増加と、それに伴う治療のための入院が、予測期間における関連薬剤の需要を牽引すると予想されます。全米希少疾患機構（National Organization for Rare Disorders, Inc.）によると、PAHの新規症例は、米国では毎年100万人当たり1～2人、欧州でも同様の発生率が予想されることから、毎年500～1000人の新規症例が発生すると推定されています。

医薬品開発のための臨床試験の新興国市場が、今後の肺動脈性肺高血圧症市場の成長を牽引すると予想されます。医薬品開発のための臨床試験は、ヒトにおける新薬や治療の安全性、有効性、潜在的な副作用を評価することを目的とした研究開発です。肺動脈性肺高血圧症に特化したこれらの臨床試験は、より効果的な新しい治療法の創出、QOLの向上、安全性と有効性の強化、早期アクセスの促進、費用対効果の高い選択肢の特定につながります。例えば、2023年5月、カナダを拠点とし、ライフサイエンスのウェビナーやバーチャルイベントを専門とするXtalks社は、2023年5月17日現在、ClinicalTrials.govに登録されている臨床研究は452,604件であると報告しました。このうち、64,838件の試験が積極的に参加者を求めており、2021年以降、登録された臨床試験は365,000件増加しています。したがって、医薬品開発のための臨床試験の増加が肺動脈性肺高血圧症市場の成長を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の肺動脈性肺高血圧症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
  • 最終用途産業の分析
  • 世界の肺動脈性肺高血圧症市場：成長率分析
  • 世界の肺動脈性肺高血圧症市場の実績：規模と成長, 2019-2024
  • 世界の肺動脈性肺高血圧症市場の予測：規模と成長, 2024-2029, 2034F
  • 世界の肺動脈性肺高血圧症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の肺動脈性肺高血圧症市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • エンドセリン受容体拮抗薬（ERA）
  • PDE-5阻害剤
  • プロスタサイクリンおよびプロスタサイクリン類似体
  • SGC刺激装置
  • 世界の肺動脈性肺高血圧症市場：ルート別管理、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 経口
  • 静脈内/皮下
  • 吸入
  • 世界の肺動脈性肺高血圧症市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 小売り
  • オンライン
  • 世界の肺動脈性肺高血圧症市場：エンドセリン受容体拮抗薬（ERA）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • ボセンタン
  • アンブリセンタン
  • マシテンタン
  • 世界の肺動脈性肺高血圧症市場：PDE-5阻害剤のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • シルデナフィル
  • タダラフィル
  • 世界の肺動脈性肺高血圧症市場：プロスタサイクリンおよびプロスタサイクリン類似体のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • エポプロステノール
  • トレプロスチニル
  • イロプロスト
  • 世界の肺動脈性肺高血圧症市場：SGC刺激装置のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • リオシグアト

第7章 地域別・国別分析

  • 世界の肺動脈性肺高血圧症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界の肺動脈性肺高血圧症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 肺動脈性肺高血圧症市場：競合情勢
  • 肺動脈性肺高血圧症市場：企業プロファイル
    • Siemens AG Overview, Products and Services, Strategy and Financial Analysis
    • Hitachi Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Wabtec Corporation Overview, Products and Services, Strategy and Financial Analysis
    • DXC Technology Company Overview, Products and Services, Strategy and Financial Analysis
    • L&T Technology Services Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • SAP SE
  • Capgemini SE
  • Cisco Systems Inc.
  • Accenture plc
  • Atkins Global
  • Trimble Inc.
  • WSP Global Inc.
  • Tego Inc.
  • KONUX GmbH
  • Oxplus B. V.
  • Bentley Systems, Incorporated
  • Trapeze Group
  • Uptake Technologies Inc.
  • Huawei Technologies Co. Ltd.
  • Cyient Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 肺動脈性肺高血圧症市場2029：新たな機会を提供する国
  • 肺動脈性肺高血圧症市場2029：新たな機会を提供するセグメント
  • 肺動脈性肺高血圧症市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r22001

Pulmonary arterial hypertension refers to a condition characterized by elevated blood pressure in the arteries of the lungs, leading to damage to the right side of the heart and the lung arteries. This long-lasting and incurable condition results in the constriction and rigidity of the walls of the pulmonary arteries. Pulmonary arterial hypertension drugs are designed to address this condition by relaxing the muscles in the blood vessel walls, increasing blood flow through the lungs, or reversing the effects of substances in the blood vessel walls that cause them to narrow.

The main types of drug classes for pulmonary arterial hypertension include endothelin receptor antagonists (ERAs), PDE-5 inhibitors, prostacyclin and prostacyclin analogs, and soluble guanylate cyclase (SGC) stimulators. Endothelin receptor antagonists (ERAs) are a targeted medication used for treating pulmonary hypertension in patients. Targeted medications aim to reduce the progression of pulmonary hypertension and potentially reverse some of the damage to the heart and lungs. These drugs can be administered through oral, intravenous/subcutaneous, and inhalational modes, and they are distributed through retail and online channels.

The pulmonary arterial hypertension market research report is one of a series of new reports from The Business Research Company that provides pulmonary arterial hypertension market statistics, including pulmonary arterial hypertension industry global market size, regional shares, competitors with a pulmonary arterial hypertension market share, detailed pulmonary arterial hypertension market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary arterial hypertension industry. This pulmonary arterial hypertension market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pulmonary arterial hypertension market size has grown strongly in recent years. It will grow from $8.47 billion in 2024 to $9.24 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to increased awareness and diagnosis of pulmonary arterial hypertension (PAH), increased healthcare expenditure, growth in aging population, expansion of pulmonary arterial hypertension treatment options, rise in research and development activities in pulmonary hypertension.

The pulmonary arterial hypertension market size is expected to see strong growth in the next few years. It will grow to $12.97 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to adoption of novel therapies for pulmonary arterial hypertension, increased focus on early detection and diagnosis, growing pipeline of PAH drugs and therapies, integration of precision medicine in PAH treatment, expansion of healthcare infrastructure in emerging markets. Major trends in the forecast period include advancements in medical imaging and diagnostic technologies, collaboration and partnerships for drug development, patient-centric approaches in pulmonary arterial hypertension management, increased use of combination therapy.

The growth of the pulmonary arterial hypertension market is being propelled by the increasing prevalence of pulmonary arterial hypertension (PAH) disease. The rise in PAH cases and the subsequent hospitalization of patients for treatment are expected to drive the demand for relevant drugs in the forecast period. According to the National Organization for Rare Disorders, Inc., a study suggests that new cases of PAH are estimated to occur in one to two individuals per million annually in the USA, equating to 500-1000 new cases each year, with similar incidence rates expected in Europe.

The increasing number of clinical trials for drug development is expected to drive the growth of the pulmonary arterial hypertension market in the future. Clinical trials for drug development are research studies aimed at assessing the safety, efficacy, and potential side effects of new drugs or treatments in humans. These trials specifically for pulmonary arterial hypertension can result in the creation of new and more effective treatments, improving quality of life, enhancing safety and efficacy, facilitating early access, and identifying cost-effective options. For example, in May 2023, Xtalks, a Canada-based company specializing in life science webinars and virtual events, reported that as of May 17, 2023, there were 452,604 clinical studies registered on ClinicalTrials.gov. Out of this total, 64,838 studies were actively seeking participants, marking an increase of 365,000 registered trials since 2021. Therefore, the rise in clinical trials for drug development is fueling the growth of the pulmonary arterial hypertension market.

Major companies in the pulmonary arterial hypertension market are developing advanced products like Winrevair to enhance treatment options and outcomes for patients with this serious condition. For example, in March 2024, Merck & Co. Inc., a US-based multinational pharmaceutical company, launched Winrevair for treating adults with pulmonary arterial hypertension. Winrevair is the first therapy approved by the Food and Drug Administration (FDA) that specifically targets activin signaling for pulmonary arterial hypertension (PAH). This innovative treatment functions by restoring the balance between pro- and anti-proliferative signals, which helps regulate the vascular cell proliferation associated with PAH. Consequently, it introduces a new class of therapy for this condition.

Major companies in the pulmonary arterial hypertension market are developing advanced products like OPSYNVI to offer improved treatment options that enhance patient outcomes and quality of life for individuals suffering from this serious condition. For example, in March 2024, Johnson & Johnson, a US-based multinational company focused on pharmaceuticals, biotechnology, and medical technologies, launched OPSYNVI for the chronic treatment of adults with pulmonary arterial hypertension. OPSYNVI can be used for patients with pulmonary arterial hypertension (PAH) who are either new to treatment or are already taking an endothelin receptor antagonist (ERA) or PDE5 inhibitor, or both. It is also appropriate for those on stable doses of macitentan 10 mg and tadalafil 40 mg, administered as separate tablets.

In May 2024, Gossamer Bio, a US-based biopharmaceutical company specializing in treatments for Pulmonary Arterial Hypertension (PAH), formed a partnership with Chiesi Farmaceutici S.p.A. This collaboration aims to leverage the strengths of both companies to enhance the treatment of pulmonary arterial hypertension (PAH) and accelerate the development of products for pulmonary hypertension associated with interstitial lung disease (PH-ILD). Chiesi Farmaceutici S.p.A. is an Italy-based pharmaceutical company.

Major companies operating in the pulmonary arterial hypertension market include United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Allegheny Health Network, Cedars-Sinai Medical Center, Cleveland Clinic, Houston Methodist Hospital, Johns Hopkins Medicine, Massachusetts General Hospital, Mayo Clinic, MedStar Heart & Vascular Institute, National Jewish Health, NewYork-Presbyterian Hospital, Ochsner Medical Center, Royal Brompton & Harefield NHS Foundation Trust, Rush University Medical Center, Stanford Health Care, Swedish Medical Center, Temple University Hospital, University of California Health.

North America was the largest region in the pulmonary arterial hypertension market in 2024. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the pulmonary arterial hypertension market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The pulmonary arterial hypertension market includes revenues earned by entities by idiopathic, heritable, and drug and toxin-induced. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pulmonary Arterial Hypertension Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pulmonary arterial hypertension market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pulmonary arterial hypertension ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pulmonary arterial hypertension market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Drug Class: Endothelin Receptor Antagonists (ERAs); PDE-5 Inhibitors; Prostacyclin and Prostacyclin Analogs; SGC Stimulators
  • 2) By Route Of Administration: Oral; Intravenous Or subcutaneous; Inhalational
  • 3) By Distribution channel: Retail; Online
  • Subsegments:
  • 1) By Endothelin Receptor Antagonists (ERAs): Bosentan; Ambrisentan; Macitentan
  • 2) By PDE-5 Inhibitors: Sildenafil; Tadalafil
  • 3) By Prostacyclin And Prostacyclin Analogs: Epoprostenol; Treprostinil; Iloprost
  • 4) By SGC Stimulators: Riociguat
  • Companies Mentioned: United Therapeutics Corporation; Acceleron Pharma Inc.; Actelion Pharmaceuticals US Inc.; Bayer AG; Eli Lilly and Company
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pulmonary Arterial Hypertension Market Characteristics

3. Pulmonary Arterial Hypertension Market Trends And Strategies

4. Pulmonary Arterial Hypertension Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Pulmonary Arterial Hypertension Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Pulmonary Arterial Hypertension PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Pulmonary Arterial Hypertension Market Growth Rate Analysis
  • 5.4. Global Pulmonary Arterial Hypertension Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Pulmonary Arterial Hypertension Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Pulmonary Arterial Hypertension Total Addressable Market (TAM)

6. Pulmonary Arterial Hypertension Market Segmentation

  • 6.1. Global Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Endothelin Receptor Antagonists (ERAs)
  • PDE-5 Inhibitors
  • Prostacyclin and Prostacyclin Analogs
  • SGC Stimulators
  • 6.2. Global Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Intravenous/ subcutaneous
  • Inhalational
  • 6.3. Global Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Retail
  • Online
  • 6.4. Global Pulmonary Arterial Hypertension Market, Sub-Segmentation Of Endothelin Receptor Antagonists (ERAs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Bosentan
  • Ambrisentan
  • Macitentan
  • 6.5. Global Pulmonary Arterial Hypertension Market, Sub-Segmentation Of PDE-5 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Sildenafil
  • Tadalafil
  • 6.6. Global Pulmonary Arterial Hypertension Market, Sub-Segmentation Of Prostacyclin And Prostacyclin Analogs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Epoprostenol
  • Treprostinil
  • Illoprost
  • 6.7. Global Pulmonary Arterial Hypertension Market, Sub-Segmentation Of SGC Stimulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Riociguat

7. Pulmonary Arterial Hypertension Market Regional And Country Analysis

  • 7.1. Global Pulmonary Arterial Hypertension Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Pulmonary Arterial Hypertension Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pulmonary Arterial Hypertension Market

  • 8.1. Asia-Pacific Pulmonary Arterial Hypertension Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pulmonary Arterial Hypertension Market

  • 9.1. China Pulmonary Arterial Hypertension Market Overview
  • 9.2. China Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pulmonary Arterial Hypertension Market

  • 10.1. India Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pulmonary Arterial Hypertension Market

  • 11.1. Japan Pulmonary Arterial Hypertension Market Overview
  • 11.2. Japan Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pulmonary Arterial Hypertension Market

  • 12.1. Australia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pulmonary Arterial Hypertension Market

  • 13.1. Indonesia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pulmonary Arterial Hypertension Market

  • 14.1. South Korea Pulmonary Arterial Hypertension Market Overview
  • 14.2. South Korea Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pulmonary Arterial Hypertension Market

  • 15.1. Western Europe Pulmonary Arterial Hypertension Market Overview
  • 15.2. Western Europe Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pulmonary Arterial Hypertension Market

  • 16.1. UK Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pulmonary Arterial Hypertension Market

  • 17.1. Germany Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pulmonary Arterial Hypertension Market

  • 18.1. France Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pulmonary Arterial Hypertension Market

  • 19.1. Italy Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pulmonary Arterial Hypertension Market

  • 20.1. Spain Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pulmonary Arterial Hypertension Market

  • 21.1. Eastern Europe Pulmonary Arterial Hypertension Market Overview
  • 21.2. Eastern Europe Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pulmonary Arterial Hypertension Market

  • 22.1. Russia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pulmonary Arterial Hypertension Market

  • 23.1. North America Pulmonary Arterial Hypertension Market Overview
  • 23.2. North America Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pulmonary Arterial Hypertension Market

  • 24.1. USA Pulmonary Arterial Hypertension Market Overview
  • 24.2. USA Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pulmonary Arterial Hypertension Market

  • 25.1. Canada Pulmonary Arterial Hypertension Market Overview
  • 25.2. Canada Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pulmonary Arterial Hypertension Market

  • 26.1. South America Pulmonary Arterial Hypertension Market Overview
  • 26.2. South America Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pulmonary Arterial Hypertension Market

  • 27.1. Brazil Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pulmonary Arterial Hypertension Market

  • 28.1. Middle East Pulmonary Arterial Hypertension Market Overview
  • 28.2. Middle East Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pulmonary Arterial Hypertension Market

  • 29.1. Africa Pulmonary Arterial Hypertension Market Overview
  • 29.2. Africa Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pulmonary Arterial Hypertension Market Competitive Landscape And Company Profiles

  • 30.1. Pulmonary Arterial Hypertension Market Competitive Landscape
  • 30.2. Pulmonary Arterial Hypertension Market Company Profiles
    • 30.2.1. Siemens AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Hitachi Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Wabtec Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. DXC Technology Company Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. L&T Technology Services Limited Overview, Products and Services, Strategy and Financial Analysis

31. Pulmonary Arterial Hypertension Market Other Major And Innovative Companies

  • 31.1. SAP SE
  • 31.2. Capgemini SE
  • 31.3. Cisco Systems Inc.
  • 31.4. Accenture plc
  • 31.5. Atkins Global
  • 31.6. Trimble Inc.
  • 31.7. WSP Global Inc.
  • 31.8. Tego Inc.
  • 31.9. KONUX GmbH
  • 31.10. Oxplus B. V.
  • 31.11. Bentley Systems, Incorporated
  • 31.12. Trapeze Group
  • 31.13. Uptake Technologies Inc.
  • 31.14. Huawei Technologies Co. Ltd.
  • 31.15. Cyient Limited

32. Global Pulmonary Arterial Hypertension Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pulmonary Arterial Hypertension Market

34. Recent Developments In The Pulmonary Arterial Hypertension Market

35. Pulmonary Arterial Hypertension Market High Potential Countries, Segments and Strategies

  • 35.1 Pulmonary Arterial Hypertension Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Pulmonary Arterial Hypertension Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Pulmonary Arterial Hypertension Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer